Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the stocks highlighted in Jim Cramer’s latest Mad Money recap as he provided top stock insights. Answering a caller’s query about the stock, Cramer said:

Too risky for me. I just think that at this stage, with this market, that one you could lose too much money. I’m very sorry.

A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for women’s cancers. The company reported its Q4 2025 and full-year earnings on March 16. It posted Q4 GAAP EPS of -$0.50, exceeding estimates by $0.01. Net loss for FY25 was $162.5 million compared to $129.5 million in the prior year.

While we acknowledge the risk and potential of OLMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OLMA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.